Sarepta Therapeutics Inc
XMUN:AB3A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sarepta Therapeutics Inc
XMUN:AB3A
|
US |
|
C
|
Conocophillips
XMUN:YCP
|
US |
|
Petro Matad Ltd
LSE:MATD
|
MN |
|
D
|
Dollar Tree Inc
DUS:DT3
|
US |
|
E
|
Euronext NV
F:ENXB
|
NL |
|
C
|
Commerzbank AG
F:CBK
|
DE |
|
S
|
Salesforce Inc
F:FOO
|
US |
|
N
|
Nextera Energy Inc
DUS:FP3
|
US |
|
C
|
Cal-Maine Foods Inc
F:CM2
|
US |
|
G
|
Garmin Ltd
F:GEY
|
CH |
|
A
|
Alibaba Group Holding Ltd
F:2RR
|
CN |
|
Rolls-Royce Holdings PLC
OTC:RYCEY
|
UK |
|
Thumzup Media Corp
NASDAQ:TZUP
|
US |
|
H
|
Halliburton Co
F:HAL
|
US |
|
S
|
Smurfit Kappa Group PLC
XMUN:SK3
|
IE |
|
G
|
Green Dot Corp
F:5GN
|
US |
|
Pharol SGPS SA
F:PTCA
|
PT |
|
C
|
CME Group Inc
XBER:MX4A
|
US |
Wall St Price Targets
AB3A Price Targets Summary
Sarepta Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AB3A is 20.04 EUR with a low forecast of 4.39 EUR and a high forecast of 34.7 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AB3A's stock price target?
Price Target
20.04
EUR
According to Wall Street analysts, the average 1-year price target for AB3A is 20.04 EUR with a low forecast of 4.39 EUR and a high forecast of 34.7 EUR.
What is the Revenue forecast for Sarepta Therapeutics Inc?
Projected CAGR
-4%
Over the last 13 years, the compound annual growth rate for Revenue has been 37%. The projected CAGR for the next 8 years is -4%.
What is the Gross Profit forecast for Sarepta Therapeutics Inc?
Projected CAGR
-2%
The compound annual growth rate for Gross Profit over the next 8 years is -2%.
